🟢 Moleculin Biotech is trading 11.55% up today after positive preliminary MIRACLE trial efficacy data

Moleculin Biotech is trading $0.64 (+11.55%) after reporting second-quarter results and positive preliminary MIRACLE trial efficacy data.

• The first 45 patients showed complete-remission rates at least three times above the control arm; enrollment toward 90 patients remains on track for September.
• The stock advanced from $0.41 on August 7 to $0.64 currently, extending a multi-session rally.
• The company reported approximately $7.3 million in June cash and subsequent $9.3 million financing proceeds.